1Grier HE, Krailo MD,Tarbell NJ,et al. Addition of ifosfamide and et-oposide to standard chemotherapy for Ewing's sarcoma and primitiveneuroectodermal tumor of bone[J]. N Engl J Med,2003,348:694 ～701.
2Miser JS, Krailo M, Meyers P, et al. Metastatic Ewing's sarcoma (ES)and primitive neuroectodermal tumor (PNET) of bone:failure of newregimens to improve outcome (abstract) [J]. Proc Am Soc Clin On-col, 1996,15:1472.
4Meyers PA,Krailo MD,Ladanyi M,et al. High-dose melphalan,etopo-side,total-body irradiation, and autologous stem-cell reconstitution asconsolidation therapy for high-risk Ewing's sarcoma does not improveprognosis[J]. J Clin Oncol,2001,19 :2812 ～ 2820.
5Leung W, Chen AR, Klann RC, et al. Frequent detection of tumorcells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. F[J]. Bone Marrow Transplant, 1998,22:971 ～ 979.
6Ladenstein R, Hartmann O, Pinkerton R, et al. A multivariate andmatched pair analysis on high-risk Ewing's tumor (ET) patients trea-ted by megatherapy (MGT) and stem cell reconstitution (SCR) inEurope [J]. Proc Am Soc Clin Oncol, 1999,18:2144.
7Lawrence W Jr, Anderson JR, Gehan EA, et al. Pretreatment TNMstaging of childhood rhabdomyosarcoma: a report of the IntergroupRhabdomyosarcoma Study Group. C [J]. Cancer, 1997,80: 1165 ～1170.
8Koscielniak E,Klingebiel TH,Peters C,et al. Do patients with meta-static and recurrent rhabdomyosarcoma benefit from high-dose therapywith hematopoietic rescue? Report of the German/Austrian PediatricBone Marrow Transplantation Group [J]. Bone Marrow Transplant,1997,19:227 ～ 231.
9Walterhouse DO, Hoover ML, Marymount MA,et al. High-dose chem-otherapy followed by peripheral blood stem cell rescue for metastaticrhabdomyosarcoma:the experience at Chicago Children's MemorialHospital[J]. Med Pediatr Oncol, 1999,32:88 ～ 92.
10Carli M, Colombatti R, Oberlin O,et al. High-dose melphalan with au-tologous stem-cell rescue in metastatic rhabdomyosarcoma[J]. J Clin Oncol, 1999,17:2793 ～ 2803.
